- Home
- WRAP vs CNTB Comparison
WRAP vs CNTB Comparison
Compare WRAP & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRAP
- CNTB
- Stock Information
- Founded
- WRAP 2016
- CNTB 2012
- Country
- WRAP United States
- CNTB United States
- Employees
- WRAP N/A
- CNTB N/A
- Industry
- WRAP Ordnance And Accessories
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- WRAP Industrials
- CNTB Health Care
- Exchange
- WRAP Nasdaq
- CNTB Nasdaq
- Market Cap
- WRAP 68.8M
- CNTB 68.5M
- IPO Year
- WRAP N/A
- CNTB 2021
- Fundamental
- Price
- WRAP $1.70
- CNTB $1.17
- Analyst Decision
- WRAP
- CNTB Strong Buy
- Analyst Count
- WRAP 0
- CNTB 1
- Target Price
- WRAP N/A
- CNTB $8.00
- AVG Volume (30 Days)
- WRAP 191.1K
- CNTB 24.6K
- Earning Date
- WRAP 10-15-2024
- CNTB 09-05-2024
- Dividend Yield
- WRAP N/A
- CNTB N/A
- EPS Growth
- WRAP N/A
- CNTB N/A
- EPS
- WRAP N/A
- CNTB N/A
- Revenue
- WRAP $7,269,000.00
- CNTB $24,116,000.00
- Revenue This Year
- WRAP N/A
- CNTB N/A
- Revenue Next Year
- WRAP N/A
- CNTB $63.90
- P/E Ratio
- WRAP N/A
- CNTB N/A
- Revenue Growth
- WRAP 0.99
- CNTB N/A
- 52 Week Low
- WRAP $1.21
- CNTB $0.68
- 52 Week High
- WRAP $7.01
- CNTB $2.84
- Technical
- Relative Strength Index (RSI)
- WRAP 56.79
- CNTB 44.02
- Support Level
- WRAP $1.71
- CNTB $1.18
- Resistance Level
- WRAP $1.93
- CNTB $1.26
- Average True Range (ATR)
- WRAP 0.16
- CNTB 0.07
- MACD
- WRAP 0.01
- CNTB -0.01
- Stochastic Oscillator
- WRAP 61.70
- CNTB 13.59
About WRAP Wrap Technologies Inc.
Wrap Technologies Inc offers public safety technologies and services. The firm develops policing solutions to law enforcement and security personnel. Its BolaWRAP 150 Remote Restraint device is a patented, hand-held tool that discharges a Kevlar cord to restrain noncompliant individuals from a range of 10-25 feet. The group operates in the Americas, Europe, the Middle East, Africa and the Asia Pacific.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.